<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Oncohematology</journal-id><journal-title-group><journal-title xml:lang="en">Oncohematology</journal-title><trans-title-group xml:lang="ru"><trans-title>Онкогематология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1818-8346</issn><issn publication-format="electronic">2413-4023</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">485</article-id><article-id pub-id-type="doi">10.17650/1818-8346-2021-16-3-33-39</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>DIAGNOSIS AND TREATMENT OF MULTIPLE MYELO</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ДИАГНОСТИКА И ЛЕЧЕНИЕ МНОЖЕСТВЕННОЙ МИЕЛОМЫ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">The role of PET/CT in the diagnosis and response assessment in patients with multiple myeloma</article-title><trans-title-group xml:lang="ru"><trans-title>Роль ПЭТ/КТ в диагностике и оценке эффекта у больных множественной миеломой</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Pankratov</surname><given-names>A. E.</given-names></name><name xml:lang="ru"><surname>Панкратов</surname><given-names>А. Е.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><bold>Aleksandr E. Pankratov </bold></p><p><italic>6B Karbysheva St., Balashikha, Moscow region 143900</italic></p></bio><bio xml:lang="ru"><p><bold>Александр Евгеньевич Панкратов </bold></p><p><italic>143900 Московская обл., Балашиха, ул. Карбышева, 6Б</italic></p></bio><email>a.pankratov@oncoart.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1564-424X</contrib-id><name-alternatives><name xml:lang="en"><surname>Zeynalova</surname><given-names>P. A.</given-names></name><name xml:lang="ru"><surname>Зейналова</surname><given-names>П. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>111 1st Uspenskoe Shosse, Lapino, Moscow region 143081</italic></p></bio><bio xml:lang="ru"><p><italic>143081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111 </italic></p></bio><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">PET-Technology Balashikha</institution></aff><aff><institution xml:lang="ru">ООО «ПЭТ-Технолоджи Балашиха»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Clinical Hospital “Lapino” of the “Mother and Child” Group of companies</institution></aff><aff><institution xml:lang="ru">Клинический госпиталь «Лапино» группы компаний «Мать и дитя»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2021-09-10" publication-format="electronic"><day>10</day><month>09</month><year>2021</year></pub-date><volume>16</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>33</fpage><lpage>39</lpage><history><date date-type="received" iso-8601-date="2021-09-09"><day>09</day><month>09</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-09-09"><day>09</day><month>09</month><year>2021</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://oncohematology.abvpress.ru/ongm/article/view/485">https://oncohematology.abvpress.ru/ongm/article/view/485</self-uri><abstract xml:lang="en"><p>A brief review focuses on the radiation diagnostics methods used in the examination of patients with myeloma and plasmacytoma. Modern imaging techniques, such as positron emission tomography combined with computed tomography (PET/CT) and magnetic resonance imaging, facilitate diagnosis and allow assessing the extent of the process and efficiency of treatment performed. Moreover, each of these methods has its own advantages and disadvantages. The most promising is PET/CT, which has sensitivity and specificity comparable to magnetic resonance imaging, while having unique advantages.</p></abstract><trans-abstract xml:lang="ru"><p>Краткий обзор посвящен методам лучевой диагностики, применяемым при обследовании пациентов с миеломной болезнью и плазмоцитомой. Современные методы визуализации, такие как позитронная эмиссионная томография, совмещенная с компьютерной томографией (ПЭТ/КТ), и магнитно-резонансная томография, облегчают постановку диагноза, позволяют оценить степень распространенности процесса и эффективность выполняемого лечения. При этом у каждого из этих методов есть свои достоинства и недостатки. Наиболее перспективной представляется ПЭТ/КТ, которая обладает сопоставимыми с магнитно-резонансной томографией чувствительностью и специфичностью, имея при этом уникальные достоинства.</p></trans-abstract><kwd-group xml:lang="en"><kwd>myeloma</kwd><kwd>plasmacytoma</kwd><kwd>positron emission tomography combined with computed tomography</kwd><kwd>radiology</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>миелома</kwd><kwd>плазмоцитома</kwd><kwd>позитронная эмиссионная томография</kwd><kwd>совмещенная с компьютерной томографией</kwd><kwd>лучевая диагностика</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Kyle R.A., Rajkumar S.V. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009;23(1):3–9. DOI: 10.1038/leu.2008.291.</mixed-citation></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Mendeleeva L.P., Votyakova O.M., Rekhtina I.G. et al. Multiple myeloma. Russian Clinical Guidelines. Moscow, 2020. Available at: https://cr.minzdrav.gov.ru/schema/144_1. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Менделеева Л.П., Вотякова О.М., Рехтина И.Г. и др. Множественная миелома. Российские клинические рекомендации. М., 2020. Доступно по: https://cr.minzdrav.gov.ru/schema/144_1.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><mixed-citation>Durie B.G. The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. Eur J Cancer 2006;42(11):1539–43. DOI: 10.1016/j.ejca.2005.11.037.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Dimopoulos M., Kyle R., Fermand J.P. et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 2011;117(18):4701–5. DOI: 10.1182/blood-2010-10-299529.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Lütje S., de Rooy J.W., Croockewit S. et al. Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma. Ann Hematol 2009;88(12):1161–8. DOI: 10.1007/s00277-009-0829-0.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Dimopoulos M., Terpos E., Comenzo R. et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. Leukemia 2009;23:1545–56. DOI: 10.1038/leu.2009.89.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>D’Sa S., Abildgaard N., Tighe J. et al. Guidelines for the use of imaging in the management of myeloma. Br J Haematol 2007;137(1):49–63. DOI: 10.1111/j.1365-2141.2007.06491.x.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Zamagni E., Cavo M. The role of imaging techniques in the management of multiple myeloma. Br J Haematol 2012;159(5): 499–513. DOI: 10.1111/bjh.12007.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Cavo M., Terpos E., Nanni C. et al. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol 2017;18(4):e206–17. DOI: 10.1016/S1470-2045(17)30189-4.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Sachpekidis C., Mai E.K., Goldschmidt H. et al. (18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate. Clin Nucl Med 2015;40(6):e300–7. DOI: 10.1097/RLU.0000000000000773.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med 2009;50(Suppl 1):11S–20S. DOI: 10.2967/jnumed.108.057182.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Caers J., Withofs N., Hillengass J. et al. The role of positron emission tomographycomputed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma. Haematologica 2014;99(4):629–37. DOI: 10.3324/haematol.2013.091918.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Bartel T.B., Haessler J., Brown T.L. et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 2009;114(10):2068–76. DOI: 10.1182/blood-2009-03-213280.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Davies F.E., Rosenthal A., Rasche L. et al. Treatment to suppression of focal lesions on positron emission tomographycomputed tomography is a therapeutic goal in newly diagnosed multiple myeloma. Haematologica 2018;103(6):1047–53. DOI: 10.3324/haematol.2017.177139.</mixed-citation></ref></ref-list></back></article>
